Endocrine Abstracts

In patients with Cushing syndrome (CS), hypercoagulability represents a significant concern, leading to elevated risk for thrombotic events. After curative surgery, hypercoagulability persists for several months; CS treatment guidelines recommend anticoagulation therapy for ≤ 3 months. In patients with Cushing disease, hemostatic parameters may even worsen after surgery, independent of surgical outcome; improvements begin ~3 months after successful surgery (Casonato ...

Cushing syndrome (CS) is a chronic and debilitating condition with high morbidity and mortality. Development of novel, safe, and effective pharmacologic therapies with improved risk-benefit profiles would enrich treatment options for patients. Relacorilant is a selective glucocorticoid receptor (GR) modulator that competitively antagonizes cortisol activity and, unlike the FDA-approved GR antagonist mifepristone, does not bind to the progesterone receptor. In a phase 2 study i...